247 related articles for article (PubMed ID: 17409748)
1. Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 24-week open-label study.
Edwards K; Royall D; Hershey L; Lichter D; Hake A; Farlow M; Pasquier F; Johnson S
Dement Geriatr Cogn Disord; 2007; 23(6):401-5. PubMed ID: 17409748
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 12-week interim analysis.
Edwards KR; Hershey L; Wray L; Bednarczyk EM; Lichter D; Farlow M; Johnson S
Dement Geriatr Cogn Disord; 2004; 17 Suppl 1():40-8. PubMed ID: 14676468
[TBL] [Abstract][Full Text] [Related]
3. A comparison of the efficacy of donepezil in Parkinson's disease with dementia and dementia with Lewy bodies.
Thomas AJ; Burn DJ; Rowan EN; Littlewood E; Newby J; Cousins D; Pakrasi S; Richardson J; Sanders J; McKeith IG
Int J Geriatr Psychiatry; 2005 Oct; 20(10):938-44. PubMed ID: 16163744
[TBL] [Abstract][Full Text] [Related]
4. Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia.
Aarsland D; Hutchinson M; Larsen JP
Int J Geriatr Psychiatry; 2003 Oct; 18(10):937-41. PubMed ID: 14533126
[TBL] [Abstract][Full Text] [Related]
5. What happens when donepezil is suddenly withdrawn? An open label trial in dementia with Lewy bodies and Parkinson's disease with dementia.
Minett TS; Thomas A; Wilkinson LM; Daniel SL; Sanders J; Richardson J; Littlewood E; Myint P; Newby J; McKeith IG
Int J Geriatr Psychiatry; 2003 Nov; 18(11):988-93. PubMed ID: 14618549
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of donepezil in patients with dementia with Lewy bodies: preliminary findings from an open-label study.
Mori S; Mori E; Iseki E; Kosaka K
Psychiatry Clin Neurosci; 2006 Apr; 60(2):190-5. PubMed ID: 16594943
[TBL] [Abstract][Full Text] [Related]
7. Galantamine treatment of vascular dementia: a randomized trial.
Auchus AP; Brashear HR; Salloway S; Korczyn AD; De Deyn PP; Gassmann-Mayer C;
Neurology; 2007 Jul; 69(5):448-58. PubMed ID: 17664404
[TBL] [Abstract][Full Text] [Related]
8. Metabolic patterns associated with the clinical response to galantamine therapy: a fludeoxyglucose f 18 positron emission tomographic study.
Mega MS; Dinov ID; Porter V; Chow G; Reback E; Davoodi P; O'Connor SM; Carter MF; Amezcua H; Cummings JL
Arch Neurol; 2005 May; 62(5):721-8. PubMed ID: 15883258
[TBL] [Abstract][Full Text] [Related]
9. Galantamine in frontotemporal dementia and primary progressive aphasia.
Kertesz A; Morlog D; Light M; Blair M; Davidson W; Jesso S; Brashear R
Dement Geriatr Cogn Disord; 2008; 25(2):178-85. PubMed ID: 18196898
[TBL] [Abstract][Full Text] [Related]
10. Report on an open-label prospective study of divalproex sodium for the behavioral and psychological symptoms of dementia as monotherapy and in combination with second-generation antipsychotic medication.
Forester B; Vanelli M; Hyde J; Perez R; Ahokpossi C; Sribney W; Adkison L
Am J Geriatr Pharmacother; 2007 Sep; 5(3):209-17. PubMed ID: 17996660
[TBL] [Abstract][Full Text] [Related]
11. Treatment of dementia in parkinsonian syndromes with cholinesterase inhibitors.
Liepelt I; Maetzler W; Blaicher HP; Gasser T; Berg D
Dement Geriatr Cogn Disord; 2007; 23(6):351-67. PubMed ID: 17389795
[TBL] [Abstract][Full Text] [Related]
12. Current treatment of dementia with Lewy bodies and dementia associated with Parkinson's disease.
Burn DJ; McKeith IG
Mov Disord; 2003 Sep; 18 Suppl 6():S72-9. PubMed ID: 14502659
[TBL] [Abstract][Full Text] [Related]
13. A case study in the treatment of dementia with Lewy bodies.
Kaufer DI
Acta Psychiatr Scand; 2004 Jul; 110(1):73-5; discussion 75-6. PubMed ID: 15180783
[TBL] [Abstract][Full Text] [Related]
14. A 2-year open-label study of galantamine therapy in Chinese Alzheimer's disease patients in Hong Kong.
Chu LW; Yik PY; Mok W; Chung CP
Int J Clin Pract; 2007 Mar; 61(3):403-10. PubMed ID: 17313606
[TBL] [Abstract][Full Text] [Related]
15. Clinical predictors of response to Acetyl Cholinesterase Inhibitors: experience from routine clinical use in Newcastle.
Pakrasi S; Mukaetova-Ladinska EB; McKeith IG; O'Brien JT
Int J Geriatr Psychiatry; 2003 Oct; 18(10):879-86. PubMed ID: 14533120
[TBL] [Abstract][Full Text] [Related]
16. Early onset effects of galantamine treatment on attention in patients with Alzheimer's disease.
Vellas B; Cunha L; Gertz HJ; De Deyn PP; Wesnes K; Hammond G; Schwalen S;
Curr Med Res Opin; 2005 Sep; 21(9):1423-9. PubMed ID: 16197661
[TBL] [Abstract][Full Text] [Related]
17. Effects of galantamine on behavioural and psychological disturbances and caregiver burden in patients with Alzheimer's disease.
Monsch AU; Giannakopoulos P;
Curr Med Res Opin; 2004 Jun; 20(6):931-8. PubMed ID: 15200752
[TBL] [Abstract][Full Text] [Related]
18. Cholinesterase inhibitors: tremor and exacerbation of Parkinson's disease.
Prescrire Int; 2007 Oct; 16(91):197-8. PubMed ID: 17926835
[TBL] [Abstract][Full Text] [Related]
19. One-week dose titration of extended release galantamine in patients with Alzheimer's disease.
Scharre DW; Shiovitz T; Zhu Y; Amatniek J
Alzheimers Dement; 2008 Jan; 4(1):30-7. PubMed ID: 18631948
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of low-dose donepezil for visual hallucinations in a patient with dementia with Lewy bodies.
Fujita Y; Takebayashi M
Psychiatry Clin Neurosci; 2010 Jun; 64(3):336. PubMed ID: 20602734
[No Abstract] [Full Text] [Related]
[Next] [New Search]
